Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

• ClinicalTrials.gov Identifier: NCT04328714
• Recruitment Status: Recruiting
• First Posted: March 31, 2020
• Last Update Posted: July 19, 2022
• Sponsor: Edwin Horwitz
• Collaborator: Ossium Health, Inc.
• Information provided by (Responsible Party): Edwin Horwitz, Emory University

Study Description

Brief Summary:

The protocol is a phase I open label study evaluating the safety and feasibility of peri-transplant infusion of freshly expanded interferon gamma primed MSCs in adult and pediatric patients undergoing HCT for acute leukemia and myelodysplastic syndrome (MDS).

Condition or disease	Intervention/treatment	Phase
Acute Leukemia; Myelodysplastic Syndromes	Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells	Phase 1

Detailed Description:

Hematopoietic cell transplantation (HCT) is an established therapeutic modality for high risk hematological malignancies in adults and children. The primary cause of morbidity and mortality after HCT is graft versus host disease (GVHD), affecting up to 70% of patients even with current prophylaxis and directly accounting for approximately a third of regimen-related death. Currently, pharmacologic prophylaxis consists of a calcineurin inhibitor and methotrexate, a drug combination introduced around 40 years ago. Despite this regimen being recognized as the standard of care, it is only partially effective, increases the risk of infection and disease relapse and imparts drug-related, short- and long-term adverse effects. Mesenchymal stromal cells (MSCs) have potent immune modulatory activity which is markedly enhanced by exposure to interferon γ. In murine models, interferon γ (IFNγ) primed MSCs (γMSCs) potently suppress GVHD without untoward adverse effects suggesting this cell therapy may markedly reduce the regimen related toxicity of HCT; however γMSCs have never been infused into patients.

This protocol is designed to test the hypothesis that freshly expanded γMSCs can be reliably produced and safely infused into patients undergoing HCT as GVHD prophylaxis.

This is an investigator-initiated Phase I study using a rolling 6, dose escalation design with two independently accruing expansion cohorts: adults and pediatrics. Accrual to the pediatric tier will commence after the maximum tolerated dose (MTD) has been determined in adults. A successful outcome of this study will lay the foundation for a future Phase II study to demonstrate efficacy and support a Phase III randomized trial.

The researchers plan to enroll a minimum of 4 and maximum of 45 subjects who are greater than 1 year old. Participants will be followed for up to 2 years after the HCT. The study will be conducted at Emory University and will recruit participants from the Winship Cancer Institute and Children's Hospital in Atlanta at Egleston.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 45 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: This study uses a rolling 6 dose escalation design with two independently accruing expansion cohorts: adults and pediatrics. Accrual in the pediatric tier will commence after the maximum dose tolerated has been determined in adults.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
• Actual Study Start Date: December 2, 2021
• Estimated Primary Completion Date: August 2023
• Estimated Study Completion Date: August 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Adult Population; Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).	Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells; To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose. Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants. Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.
Experimental: Pediatric Population; Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).	Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells; To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose. Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants. Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.

Outcome Measures

Primary Outcome Measures :

1. Number of successful preparations and deliveries of investigational product [ Time Frame: Day 1 (day of infusion) ]
   Feasibility will be documented by successful γMSC preparation and delivery to the bedside. If an adverse event precludes initiation or completion of the infusion, this MSC preparation/infusion will, nonetheless, be considered feasible. Processing scored as a not feasible will consist of a cell preparation does not meet release criteria.
2. Number of adverse events attributed to the investigational product [ Time Frame: Day 2 (day after infusion) ]
   Safety will be assessed by toxicity grading according to the Common Terminology Criteria for Adverse Events, version 4 (CTCAEv4). All recorded adverse events and serious adverse events will be documented and recorded. Their attribution to γMSCs will be determined. Dose limiting toxicity definition: For this study, dose limiting toxicities (DLTs) will be defined as any grade ≥3 adverse reaction AND attributable to γMSCs (attribution listed as at least probable), occurring from γMSC infusion through the day of hematopoietic engraftment or 21 days of transplant, whichever is later.
3. Maximal Tolerated Dose [ Time Frame: Day 2 (day after infusion) ]
   The maximal tolerated dose will be the dose at which 0 of 3 or 1 of 6 subjects demonstrates a DLT. If a dose of 10 x 106 γMSCs/kg is determined to be safe, then we will not determine the true MTD and accept 10 x 106 γMSCs/kg as the maximal dose.

Secondary Outcome Measures :

1. Primary graft failure [ Time Frame: Up to Year 2 ]
   This endpoint will be defined as lack of neutrophil recovery (defined as ANC > 500/μL for three consecutive days) by 42 days post-transplant or neutrophil recovery with lack of myeloid donor chimerism. Relapse and death prior to neutrophil engraftment are considered competing risks for the endpoint of primary graft failure.
2. Secondary graft failure [ Time Frame: Up to Year 2 ]
   Secondary graft failure is defined as initial donor-derived neutrophil engraftment followed by subsequent decline in absolute neutrophil count (ANC) to < 500/μL for fourteen consecutive measurements on different days, and unresponsive to growth factor therapy, with loss of donor chimerism to < 50%.
3. Platelet engraftment [ Time Frame: Up to Year 2 ]
   Platelet engraftment is defined as the first day of a minimum of three consecutive measurements on different days such that the patient has achieved a platelet count > 20,000/μL and > 50,000/μL with no platelet transfusions in the preceding seven days. The first day of the three measurements will be designated as the day of platelet engraftment.
4. Non-relapse mortality (NRM) [ Time Frame: Up to Year 2 ]
   The event is death in continuous remission treating relapse as the competing risk. Patients alive and in remission at the time of last observation will be censored.
5. Change in Acute graft-versus-host disease (aGvHD) Incidence [ Time Frame: Day 30, Day 100 ]
   Incidences of grade II-IV and III-IV acute GvHD will be measured according to Revised Glucksberg criteria.
6. Change in Chronic graft-versus-host disease (cGvHD) Incidence [ Time Frame: Day 30, Day 100, Day 180, Day 365 ]
   Incidence of chronic GvHD will be scored according to the recent NIH scoring.
7. Disease-free survival (DFS) [ Time Frame: Up to Year 2 ]
   Disease-free survival is defined as the minimum time interval from transplant to relapse/recurrence of disease, to death or to last follow-up.
8. Primary cause of death [ Time Frame: Up to Year 2 ]

   Primary cause of death will be classified as:

   Relapse/Primary disease: If the patient relapsed/progressed after day 0 prior to death, the primary cause of death is relapse/progression, even if they subsequently developed GvHD, organ toxicities or infections that may have contributed to subsequent death. GvHD: Death from acute or chronic GvHD, in the absence of relapse or disease progression.

   Infection: Death from documented viral, bacterial or fungal infections in the absence of GvHD or relapse/disease progression.

   Organ toxicity: Death from major organ toxicities not attributable to acute myeloid leukemia (AML)/MDS, infection or GvHD.

   Other: Any other causes of death.

9. Relapse [ Time Frame: Up to Year 2 ]
   Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, acute lymphoblastic leukemia (ALL) or MDS and including minimal residual disease (MRD) in ALL consistent with pre-transplant features. The event for this endpoint is the time interval from transplant to relapse/recurrence of disease or to last follow-up. Death in remission is considered a competing risk.
10. Early discontinuation [ Time Frame: Up to Year 2 ]
    If a patient is enrolled on the study but does not start protocol treatment, a study exit form must be submitted documenting the reason for not starting protocol treatment. Such a subject will not be considered evaluable.
11. Viral activation [ Time Frame: Up to Day 100 ]
    Viral activations of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) will be documented. For the purpose of the study viral activation is defined as any polymerase chain reaction (PCR) assay result considered positive by Laboratory Medicine which may or may not lead to the initiation of antiviral therapy as per institutional guidelines.

Eligibility Criteria

• Ages Eligible for Study: 1 Year and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• All transplant patients who undergo HCT with a myeloablative (MA) or Fludarabine/Melphalan (RIC) conditioning regimen and a HLA A- B- C- DR-matched unrelated donor as treatment for hematologic malignancy or MDS.
• Age ≥ 1 year at the time that the informed consent document is signed.
• Patients with acute leukemia must be in complete remission (defined as an M1 marrow -<5% blasts- no evidence of extramedullary disease. Complete remissions without platelet recovery (CRp) will be considered remissions.
• Planned GVHD prophylaxis with a calcineurin inhibitor and methotrexate per institutional standards.
• Subject or parent/guardian must sign an informed consent document, and if appropriate, children must sign an assent document.

Exclusion Criteria:

• Patients who are to receive a non-myeloablative conditioning regimen.
• Patients receiving another investigational drug for acute GVHD prevention during the conditioning regimen or a planned investigational drug for the first year after transplant (there are no restrictions on GVHD treatment).
• Any medical or psychological condition or situation deemed by the Investigators to put the patient at increased risk of complications or non-compliance.
• Patient with a secondary malignancy who would be otherwise eligible for study, but for whom remission from the primary disease cannot be conclusively confirmed or for whom the chance of relapse of the primary disease is significant.
• Pregnancy (positive serum b-HCG) or breastfeeding.
• Estimated glomerular filtration rate (GFR) of < 50 mL/min/1.73m2.
• Cardiac ejection fraction < 50 (using M-Mode if assessment is done by Echocardiogram)
• T bilirubin > 2 × upper limit of normal or alanine aminotransferase (ALT) > 4 × upper limit of normal or aspartate aminotransferase (AST) > 4 x upper limit of normal unresolved veno-occlusive disease
• Pulmonary disease with forced vital capacity (FVC), forced expiratory volume (FEV1) or diffusing capacity for carbon monoxide (DLCO) parameters <45% predicted (corrected for hemoglobin) or requiring supplemental oxygen. Children who are developmentally unable to perform pulmonary function testing will be assessed solely on their need for supplemental oxygen.
• Karnofsky performance score or Lansky Play-Performance Scale score <80
• Human leukocyte antigen (HLA) antibody screen positive for HLA antibodies specific against the MSC products.

Contacts and Locations

Contacts

Contact: Muna Qayed, MD; 404-785-1441; mqayed@emory.edu

Locations

United States, Georgia

Children's Healthcare of Atlanta at Egleston; Recruiting

Atlanta, Georgia, United States, 30322

Emory University; Recruiting

Atlanta, Georgia, United States, 30322

Winship Cancer Institute of Emory University; Recruiting

Atlanta, Georgia, United States, 30322

Sponsors and Collaborators

Edwin Horwitz

Ossium Health, Inc.

Investigators

• Principal Investigator: Muna Qayed, MD; Emory University

More Information

• Responsible Party: Edwin Horwitz, Professor, Emory University
• ClinicalTrials.gov Identifier: NCT04328714
• Other Study ID Numbers: IRB00105305
• First Posted: March 31, 2020
• Last Update Posted: July 19, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Individual participant data that underlie the results reported in the published article will be made available for sharing. T cell repertoire data will be submitted to a public data base.
• Supporting Materials: Study Protocol
• Time Frame: Data will be made available upon publication of the article and sharing will end 36 months after publication.
• Access Criteria: Data will be available to anyone upon written(email) request to the study sponsor. Requestors will need to sign a data access agreement and will be prohibited from passing it on to a third party.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Edwin Horwitz, Emory University:

Interferon Gamma (IFN γ); Graft versus Host Disease (GVHD); Allogeneic Hematopoietic Cell Transplantation

Additional relevant MeSH terms:

Myelodysplastic Syndromes; Bone Marrow Diseases; Hematologic Diseases; Interferons; Interferon-gamma; Antineoplastic Agents; Antiviral Agents; Anti-Infective Agents